Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

Therapeutics Research

van Kuijk AW, Vergunst CE, Gerlag DM et al. Ann Rheum Dis 2010;69:2013–6.

The C-C chemokine receptor CCR5 binds chemo-attractants that guide the migration of pro-inflammatory monocytes/macrophages and T cells to the joint. Interrupting this pathway might be a promising treatment strategy in patients with autoimmune arthritis.

 

Chemokines are essential factors in the trafficking of leukocytes. Treatment with a CCR5 antagonist ameliorates collagen-induced arthritis in rhesus monkeys [1]. The present study investigated the clinical effects and safety of SCH351125, an oral, small-molecule antagonist of the CCR5 receptor, in patients with active rheumatoid arthritis (RA).

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles